REFERENCES
1. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015;66:2451-66.
2. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-84.
3. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117-24.
4. Suhr OB, Wixner J, Anan I, et al. Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families. PLoS One 2019;14:e0211983.
5. Ihse E, Rapezzi C, Merlini G, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 2013;20:142-50.
6. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113-22.
7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
8. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and Pericardial diseases. Eur Heart J 2021;42:1554-68.
9. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872-91.
10. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8.
11. Conceição I, González-Duarte A, Obici L, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 2016;21:5-9.
12. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid 2021;28:12-8.
13. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
14. Damy T, Kristen AV, Suhr OB, et al. THAOS Investigators. Transthyretin cardiac amyloidosis in continental western europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J ;2019:391-400.
15. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013;29:63-76.
16. Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin amyloidosis outcomes survey (THAOS) registry: design and methodology. Curr Med Res Opin 2013;29:77-84.
17. Maurer MS, Hanna M, Grogan M, et al. THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin amyloid outcome survey). J Am Coll Cardiol 2016;68:161-72.
18. Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 2007;35:116-8.
19. Gagliardi C, Perfetto F, Lorenzini M, et al. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. Eur J Heart Fail 2018;20:1417-25.
20. Quarta C, Longhi S, Cappelli F, et al. Late onset cardiomyopathy due to transthyretin Ile68Leu mutation: a cardiogenic variant of familial amyloidosis potentially mimicking sarcomeric hypertrophic cardiomyopathy. European Heart J 2013;34:P2958-P2958.
21. Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y. THAOS investigators. Characteristics of patients with late-vs early-onset val30met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther 2021;10:753-66.
22. Gentile L, Tournev I, Amass L, Chapman D, Mazzeo A. THAOS investigators. phenotypic differences of glu89gln genotype in ATTR amyloidosis from endemic loci: update from THAOS. Cardiol Ther 2021;10:481-90.
23. Parman Y, Adams D, Obici L, et al. European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? Curr Opin Neurol 2016;29 Suppl 1:S3-S13.
24. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-53.
25. Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007;7:2597-604.
26. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015;372:21-9.
27. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7.
28. Mazzeo A, Russo M, Di Bella G, et al. Transthyretin-related familial amyloid polyneuropathy (ttr-fap): a single-center experience in sicily, an italian endemic area. J Neuromuscul Dis 2015;2:S39-48.
29. Mariani LL, Lozeron P, Théaudin M, et al. French Familial Amyloid Polyneuropathies Network (CORNAMYL) Study Group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015;78:901-16.
30. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 2008;216:253-61.
31. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012;93:1017-23.
32. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 2016;121:17-24.
33. Caponetti AG, Rapezzi C, Gagliardi C, et al. THAOS Investigators. Sex-related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS. JACC Heart Fail 2021;9:736-46.
34. Batra J, Rosenblum H, Defilippis EM, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile mutation: insights from noninvasive pressure-volume analysis. J Card Fail 2021;27:67-74.
35. Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008;15:40-8.
36. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-6.
37. Iorio A, De Lillo A, De Angelis F, et al. Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet 2017;25:1055-60.
38. Alves-Ferreira M, Azevedo A, Coelho T, et al. Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis. Amyloid 2021;28:100-6.
39. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes. Amyloid 2013;20:256-62.
40. Musunuru K, Hershberger RE, Day SM, et al. American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American heart association. Circ Genom Precis Med 2020;13:e000067.
41. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019;7:709-16.
42. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
43. Musumeci MB, Cappelli F, Russo D, et al. Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:1314-21.
44. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019;12:e006075.
45. Benson MD, Dasgupta NR, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag 2020;16:749-58.
46. Gopal DM, Ruberg FL, Siddiqi OK. Impact of genetic testing in transthyretin (ATTR) cardiac amyloidosis. Curr Heart Fail Rep 2019;16:180-8.
47. Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 2021;268:2109-22.
48. Schmidt HH, Barroso F, González-Duarte A, et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2016;54:353-60.
49. Obici L, Kuks JB, Buades J, et al. European Network for TTR-FAP (ATTReuNET). Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 2016;29 Suppl 1:S27-35.
50. Guimarães L, Sequeiros J, Skirton H, Paneque M. What counts as effective genetic counselling for presymptomatic testing in late-onset disorders? J Genet Couns 2013;22:437-47.
51. Olsson M, Jonasson J, Cederquist K, Suhr OB. Frequency of the transthyretin Val30Met mutation in the northern Swedish population. Amyloid 2014;21:18-20.
52. Magliano L, Obici L, Sforzini C, et al. ATTRv Collaborators. Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet J Rare Dis 2021;16:163.
53. Graceffa A, Russo M, Vita GL, et al. Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. Neuromuscul Disord 2009;19:44-8.
54. Grandis M, Obici L, Luigetti M, et al. Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus. Orphanet J Rare Dis 2020;15:348.
55. Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 2019;26:3-9.
56. Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging 2014;7:531-2.
57. Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging 2017;10:713-4.
58. Leonardi L, Adam C, Beaudonnet G, et al. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis. Eur J Neurol 2022;29:1477-87.
